Use of GPR30 receptor ligands to mediate neurotrophic action
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsWilliam C. Mobley, Ronald J. Weigel, Chengbiao Wu, Har Hiu Dawn Lam
Life of this patent
Estimating the term…
Abstract
Neurological dysfunction is prevented or treated by the administration of ligands that activate the GPR30 receptor. Ligands include estrogens and structurally related molecules. Preferably the GPR30 ligand is an orally available drug that can cross into the brain from blood. Screening methods are provided for ligands that do not activate other estrogen receptors, and therefore do not have the classical estrogenic effects attributable to these receptors.
Claims5
A method of increasing neurotrophic activity in a neural cell, the method comprising:
- administering an effective dose of a GPR30 ligand that activates GPR30 receptor, but not ESR1 or ESR2, to a neural cell expressing said GPR30 receptor,
- wherein activation of said GPR30 receptor increases neurotrophic activity in said neural cell.
Dependencies are inferred from the claim text.